Alector has identified 40 immune system targets and has 10 drugs in preclinical research, and is taking two potential drugs into early stage clinical trials. AL001, initially aimed at treating a ...

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in ...

Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the efficacy and safety of AL101/GSK4527226, in individuals with early Alzheimer ...

Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.

I n a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a 52-week low, sinking to $1.59. With a market capitalization of $158.65 million, InvestingPro analysis suggests ...

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...

April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...